Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis (EXEL), an oncology-focused biotech firm, is highlighted as a strong growth stock by Zacks, holding a #2 (Buy) rank and an 'A' for both its VGM and Growth Style Scores. The company's fiscal year earnings are projected to grow by 28.5%, and the consensus earnings estimate for fiscal 2025 has increased by $0.26 to $2.57 per share following upward revisions by nine analysts in the last two months, indicating positive momentum.

Analysis

Exelixis (EXEL), an oncology-focused biotechnology company, presents a compelling growth profile based on Zacks Investment Research's proprietary metrics. The company holds a Zacks Rank #2 (Buy), indicating a positive short-term outlook, and is further distinguished by an 'A' grade for both its overall VGM (Value, Growth, Momentum) Score and its specific Growth Style Score. This robust assessment is underpinned by a significant projected year-over-year earnings growth of 28.5% for the current fiscal year. Analyst sentiment towards EXEL's future profitability has strengthened, evidenced by nine upward earnings estimate revisions for fiscal 2025 within the last 60 days. Consequently, the Zacks Consensus Estimate for fiscal 2025 earnings per share has risen by $0.26 to $2.57. Moreover, Exelixis has demonstrated a consistent ability to surpass expectations, with an average earnings surprise of 48.6%. These quantitative indicators, combined with a per-ticker sentiment score of 0.9 (very positive), highlight a favorable fundamental and sentiment-driven outlook for the company.

Key Decisions for Investors

• Investors with a growth-oriented strategy should consider Exelixis, given its strong Zacks Rank #2 (Buy), 'A' rated Growth and VGM scores, and a substantial 28.5% projected earnings growth for the current fiscal year.
• The positive trend in analyst earnings revisions, with nine upward adjustments for fiscal 2025 leading to a consensus EPS of $2.57, alongside a 48.6% average earnings surprise, suggests monitoring upcoming earnings reports for continued outperformance.
• Given the strong quantitative signals and positive analyst sentiment, further due diligence on EXEL is warranted, particularly for portfolios seeking exposure to the oncology biotechnology sector with demonstrated growth characteristics.